Is a Universal Flu Vaccine on the Way?

Your next video will start in

Recommended Videos

  • Info

  • Comments


Sept. 10 (Bloomberg) -- Jack Rosen, a BiondVax board member, discusses the company's development of a universal flu vaccine with Scarlet Fu on Bloomberg Television's "Money Moves." (Source: Bloomberg)

Colleague, scarlet fu.

Developing a universal flu vaccine.

Tell us about the distinction is that this person is the first is what is generally available right now.

Vaccines that are specifically targeted.

This one is the universal vaccine.

Clinical trials have indicated it can be used to immune the wide variety of influenza and some of the pandemic clues we have seen in recent years.

So it potentially can be used for all flus and all potential pandemic outbreaks.

How close is it to getting acceptance?

It has gone through several clinical trials.

It just apply to the fda and waiting for approval for the next phase two clinical trial.

At the moment we are seeking a partner to a phase 3 trials.

We're talking to a number of companies that could take as little as a year or two once refined a partner.

Tell me about the level of interest in funding verses outside israel.

To go there is a great deal of interest in finding new drugs, as you know.

And i think being in israel is somewhat of a smaller market so you do not get the international attention, so it is somewhat more difficult.

Being on the tel aviv stock exchange does not give you the same exposure.

If you look at a couple of the competitors that are also trying to develop a universal vaccine, they are selling at a far higher market cap, some of them at a hundred million dollars.

I think a lot of it is a question of exposure, and the company is taking a look at the difficulty right now.

Jack rosen, a board member

This text has been automatically generated. It may not be 100% accurate.


BTV Channel Finder


ZIP is required for U.S. locations

Bloomberg Television in   change